Although studies showed that the inhibition of NF-κB activation through the stabilization of NF-κB-inhibitory protein IKBɑ upon BTZ treatment [67, 68] contributes effectively to the anti-tumor efficacy of BTZ in cancer [69, 70], we cannot exclude the possibility that also other mechanisms contribute to the observed effect. Here, NFKB1 is linked to neoplasm.